NFE2L2 and major depressive disorder: These data demonstrate that meloxicam’s ability to suppress hippocampal NOX1/NOX4 pro-oxidant signals and enhance the antioxidant Nrf2/HO-1 pathway is, at least partly, implicated in the mitigation of depression manifestations in animals.